{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018578","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.944608+00:00","generated_at":"2026-06-08T07:35:43.913655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio reports Q3 net loss of $16.7M; cash runway into Q2 2024; XTX202 shows 50% DCR at ≥2.8 mg/kg","bullets":["Net loss $16.7M vs $19.8M YoY; R&D spend $11.1M, G&A $6.3M.","Cash $59.8M (Sep 30) vs $120.4M (Dec 31); runway into Q2 2024.","XTX202 Phase 1/2: 50% disease control rate at ≥2.8 mg/kg; no vascular leak syndrome.","XTX101: >70% tumor activation in biopsies; clinical trial collaboration with Roche to start combo with atezolizumab in Q4 2023.","XTX301 preliminary Phase 1 safety data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018578","json":"https://secwatch.observer/filing/0001558370-23-018578.json","markdown":"https://secwatch.observer/filing/0001558370-23-018578.md","text":"https://secwatch.observer/filing/0001558370-23-018578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/0001558370-23-018578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/xlo-20231109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:35:43.913655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cc725ce906f3e75a1ed77e6ad5c1ea9513f8514","claim":"Xilio Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/0001558370-23-018578-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}